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Phenotypic screening Approaches to 
develop Aurora Kinase Inhibitors: 
drug discovery Perspectives
Carlos Marugán, Raquel Torres and María José Lallena*
Discovery Chemistry Research and Technology, Lilly Research Laboratories, Eli Lilly and Company, Alcobendas, Spain
Targeting mitotic regulators as a strategy to fight cancer implies the development of 
drugs against key proteins, such as Aurora-A and -B. Current drugs, which target mito-
sis through a general mechanism of action (stabilization/destabilization of microtubules), 
have several side effects (neutropenia, alopecia, and emesis). Pharmaceutical companies 
aim at avoiding these unwanted effects by generating improved and selective drugs that 
increase the quality of life of the patients. However, the development of these drugs is an 
ambitious task that involves testing thousands of compounds through biochemical and 
cell-based assays. In addition, molecules usually target complex biological processes, 
involving several proteins and different molecular pathways, further emphasizing the 
need for high-throughput screening techniques and multiplexing technologies in order 
to identify drugs with the desired phenotype. We will briefly describe two multiplexing 
technologies [high-content imaging (HCI) and flow cytometry] and two key processes for 
drug discovery research (assay development and validation) following our own published 
industry quality standards. We will further focus on HCI as a useful tool for phenotypic 
screening and will provide a concrete example of HCI assay to detect Aurora-A or -B 
selective inhibitors discriminating the off-target effects related to the inhibition of other 
cell cycle or non-cell cycle key regulators. Finally, we will describe other assays that can 
help to characterize the in vitro pharmacology of the inhibitors.
Keywords: high-content imaging, assay development, cell cycle, ph3s10, Aurora kinases
INtRodUCtIoN
Aurora-A and Aurora-B are two serine threonine kinases that regulate cell cycle progression from 
G2 through to cytokinesis in a coordinated manner even though their localization and activation 
timing during the cell cycle varies. Aurora-A is required for mitotic entry, centrosome maturation 
and separation, and chromosome alignment (1), whereas Aurora-B is involved in chromosome 
condensation, segregation, and cytokinesis by regulating microtubule kinetochore associations (2). 
Inhibition of any of these two kinases will produce a different phenotype, while Aurora-A inhibi-
tion delays mitotic entry and progression and accumulates cells in G2/M phase (3, 4), Aurora-B 
inhibition prevents proper alignment of chromosomes to the spindle plate, inhibits cytokinesis, and 
results in the formation of multinucleated cells (5). However, the fact that human Aurora-A and -B 
share 71% identity in its carboxy-terminal catalytic domain is critical for evaluating the specificity 
of inhibitors (6).
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Classic antimitotic drugs such as spindle poisons (e.g., taxa-
nes and vinka alkaloids) prevent microtubule dynamics. Since 
microtubules, besides its mitotic role, are also necessary for 
multiple cellular functions during interphase, the use of these 
drugs is associated with side-effects such as neurotoxicity that 
can lead to irreversible neuropathologies (7). As opposed to pre-
vious molecules, inhibitors against specific therapeutical targets 
and focused on patients with specific characteristics (patient 
tailoring) need to be discovered. The pharmaceutical industry 
is evolving to fulfill this need, a tendency that can be observed 
in the development of CDK inhibitors. With approximately 
14 molecules in clinical trials, the first generation molecules 
are often pan-CDK inhibitors (e.g., flavopiridol), whereas the 
more recent molecules tend to focus in specific CDKs (e.g., 
palbociclib and abemaciclib against CDK4/6) (8). The same 
concept applies for molecules against Aurora kinases, where 
most clinical trials have focused on Aurora-A selective agents 
(53%) as opposed to Pan-Aurora (32%) and Aurora-B-specific 
compounds (15%) (9).
In cancer treatment, there are mainly two approaches to 
inhibit a target: small molecules (e.g., gemcitabine against lung 
and pancreatic cancer) and large molecules (e.g., trastuzumab 
against ERBB2-overexpressing/amplified tumors). Large mol-
ecules include recombinant proteins and monoclonal antibodies 
and are often referred to as “biotech” drugs. (10). Whereas large 
molecules tend to be administered intravenously, small mol-
ecules usually allow easier administration (oral) but tend to be 
less selective. To discover a small molecule against a new target, 
pharmaceutical companies usually test thousands of compounds 
through biochemical assays, followed by a reduced number of 
compounds through cell-based assays and an even minor quan-
tity through in vivo assays. Testing such an amount of compounds 
rapidly required the development of automation platforms and 
other technologies that allow the use of high-throughput screen-
ing (HTS) techniques. Usually, the molecular targets for cancer 
therapy are involved in complex biological processes and they 
interact with others from the same or even different molecular 
pathways. This adds a degree of difficulty to drug discovery in 
general and to assay development in particular. All of the above 
highlights the need for multiplexing technologies that allow for 
the evaluation of several readouts in the same experiment. Both, 
on-target and off-target effects will indicate the selectivity of the 
compounds, which ultimately, together with oral administration 
and safety profile, are the main desirable properties of a final drug 
candidate.
MULtIPLeXING teChNoLoGIes
Singleplex technologies such as cell viability assays fall short in 
guaranteeing that the observed cellular effect upon compound 
treatment is due to inhibiting the target of interest. Off-target 
effects could create false positives and considering the challenge 
of selective compound properties, new technologies to monitor 
phenotypic changes associated with target inhibition are required. 
High-content imaging (HCI) and flow cytometry are two of the 
most commonly used techniques.
high-Content Imaging
Also called high-content screening, HCI is a technique where 
a few hundred or a few thousand perturbagens (compounds, 
drugs, siRNAs, and cDNAs) are tested and scores of parameters 
are recorded from each individual cell using multiple imaging 
channels. The readouts can be kinetic and single endpoint using 
live and fixed cells, respectively (11).
The technology is based on obtaining one or several images 
of every sample, usually placed in wells of 96-well, 384-well, 
or even 1536-well microplates to achieve high throughput. For 
that purpose, two major types of detectors can be used: digital 
cameras and photomultiplier tubes (PMTs). The images can later 
be analyzed and managed by using specific software that usually 
comes with the instrument.
The assay type is an immunocytofluorescence assay and the 
selection of the proper antibody that recognizes the protein of 
interest is of importance. Usually, a secondary antibody is used 
to increase specificity and amplify the signal. These secondary 
antibodies are conjugated with fluorescent dyes that have a wide 
variety of absorption and emission wavelengths, allowing multi-
plexing while minimizing overlapping spectra (e.g., Alexa Fluor®).
There are basically three types of instruments according to the 
detection technology used: wide field imagers (often built around 
inverted research microscopes), confocal HCA imagers (confo-
cal microscopes, preferred for live cell imaging and best used for 
imaging small intra-cellular structures, small cells, complex 3-D 
structures and samples with strong background fluorescence), 
and laser scanning cytometers (conceptually similar to a flatbed 
scanner with laser beams scanned across the entire surface of the 
plate and fluorescence detected with PMTs, good at detecting 
cells but not subcellular features or processes) (11).
Flow Cytometry
This technique goes back to the invention of the first devices 
based on the Coulter principle to sort cell populations (12). 
Nowadays, fluorescence-based methods are used for the detec-
tion of biomarkers, cell counting, and sorting.
One of the key principles of flow cytometry is a process 
called hydrodynamic focusing. Basically, the fluidics system of 
the machine allows it to order the sample in solution that has 
been injected (where particles are randomly distributed in three-
dimensional space) into a stream of single particles that can be 
interrogated by the detection system. Subsequently, each particle 
passes through one or more beams of light. Light scattering or 
fluorescence emission provides information about the particle’s 
properties. The laser and the arc lamp are the most commonly 
used light sources in modern flow cytometry (13).
With the possibility to analyze single cell events out of cellular 
aggregates or clusters, flow cytometry overcomes one of the main 
disadvantages of HCI. However, working with formats such as 
384-well plates in flow cytometry is more complex than in HCI, 
requiring additional optimization to improve signal homogeneity 
and reading time.
A wide array of phenotypic changes can be chosen as readout: 
changes in morphology, protein translocation and expression, 
FIGURe 1 | Assay development flow chart.
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alteration of the phosphorylation status of proteins, changes in 
DNA content (e.g., Aur B inhibition usually leads to endoreplica-
tion and an increase of cells with 8N and beyond), and epigenetic 
modifications (e.g., H3K27). Both, HCI and flow cytometry 
allow for the development of novel cell-based assays to define 
the in vitro efficacy of new molecules. Through a combination of 
the multiple readouts mentioned above, we can detect both on-
target and off-target effects of the drug and can evaluate the most 
appropriate concentration of a drug and the accurate cellular 
exposure to achieve the desired phenotype. These parameters are 
of importance for the design of the in vivo dosing schedule and 
eventually for a successful drug discovery process.
IMPLeMeNtAtIoN, oPtIMIZAtIoN, ANd 
VALIdAtIoN oF hIGh-thRoUGhPUt 
AssAYs
Assay development
When setting up a cell-based assay for screening for the first 
time, there are several steps that should be followed [Figure 1; 
(11)]. One of the first steps is to select the cell lines for the study. 
Through the use of internal or external cell sensitivity panels and 
published scientific articles, cell lines with an anticipated response 
to the target of interest (e.g., Aurora kinases) could be identified. 
This will not only help to select the most appropriate cell lines 
for the assay but also open the possibility to study the genetic 
background of those cell lines to establish a connection with 
target inhibition leading to a proper patient-tailoring strategy. As 
a counterscreening for toxicity, a non-sensitive cell line can be 
selected or other readouts can be added to the sensitive cell lines 
(for example, apoptosis or senescence) to confirm the cause of cell 
proliferation inhibition.
Another parameter that would need to be considered is if and 
how the target protein is expressed in the cellular model of inter-
est. This will provide an idea of the possible readouts for the assay: 
monitor directly changes in protein expression, phosphorylation, 
or location; surrogate readouts such as phenotypic changes; or 
even a combination of both.
Once the cell lines have been selected, according to the 
expected throughput of the assay generally either 96-well or 
384-well plates will be chosen to seed the cells. Growth condi-
tions and the appropriate cell seeding density will also need to 
be determined. Clear bottoms are required in these wells, so the 
lasers can excite the sample. If using poorly adherent cells, it is 
useful to plate the cells in wells coated with extracellular matrix 
components (e.g., poly-d-lysine, collagen, etc.).
Fixing and staining steps are quite similar to those of an 
immunofluorescence assay. The reagents used can be optimized 
according to the cell line and antibody that have been selected. 
Reagents to be optimized include salt-based solutions (Hank’s 
balanced salt solution, phosphate-buffered saline, and Tris-
buffered saline), fixatives (formaldehyde, methanol, or other non-
toxic fixative reagents), permeabilization buffers (salt solutions 
or water containing detergents, such as Triton X-100, Tween-20, 
SDS, and NP-40), blocking buffers (BSA, milk, and FBS), and the 
antibodies (concentration).
It is critical which type of compounds will be used (agonists, 
antagonists or both) and whether there is an available reference 
compound. Moreover, the DMSO tolerance of the cells and the 
period of time that the cells will be incubated with the compounds 
are important factors for the assay. The treatment duration depends 
on the type of response and the doubling time of the cell line used, 
e.g., changes in phosphorylation usually can be monitored within 
hours whereas changes in DNA content will require more time.
The number of lasers and detection channels available in the 
HCI instrument is essential for the readouts for the assay. These 
instruments will allow the use of DAPI/Hoechst or propidium 
iodide to stain the nuclei and different secondary antibodies.
Setting Up a Flow Scheme
Biochemical assays are an easy way to rapidly evaluate thousands 
of molecules and select a reduced number of molecules for their 
further characterization in cell-based assays.
Basically, several biochemical assays are set up for the enzymes 
of interest and others closely related, either from the same family 
(Aurora-A and -B) or involved in the same pathway (CDKs, PLK1, 
etc.). Usually, the inhibition of the latter ones should be avoided to 
ensure that the phenotypic outcome of the cell-based assay is due 
to inhibition of the target of interest (Aurora). Several techniques 
can be used to monitor biochemically the effect produced by 
the compounds: radioactivity, fluorescence, luminescence, mass 
spectrometry, etc. These assays will allow for the selection of the 
best molecules according to potency and selectivity to be tested 
in the cell-based assays.
Both, biochemical and cell-based assays, along with novel 
biophysical techniques, are used to evaluate structure–activity 
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FIGURe 2 | example of concentration–response curve plate format for plate uniformity assessment (96-well plates). (A) CRC plate. (B) “Max” plate.  
(C) “Min” plate.
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relationship (SAR) and design improved versions of the molecule. 
The more advanced molecules would be studied in-depth by 
testing several cell lines to confirm a link between genetic back-
ground and drug sensitivity. Drug combination with standards of 
care could also be addressed. Finally, the molecules will be tested 
in vivo to confirm the efficacy, and to evaluate whether they will 
proceed to clinical studies.
Thus, the flow scheme determines the different stages the 
compounds will go through before determining a candidate 
molecule for clinical trials. The assays included in the flow 
scheme need to be biologically significant for the targeted 
disease and the different stages need to show a desirable degree 
of connectivity.
Assay Validation
Due to the high number of compounds to be evaluated, the 
assays need to be reproducible overtime and independently of 
the operator performing the assay. For that reason, there is a clear 
need for strict assay validation criteria that assure high quality 
data. When validating a new assay, we will require two different 
types of validation assays: a 3-day plate uniformity study and a 
replicate-experiment study.
Plate Uniformity
Uniformity assays are performed at the maximum and minimum 
signal or response levels to ensure that the signal window is ade-
quate to detect active compounds during the screen. Therefore, 
the variability tests are conducted on three types of signals: “Max” 
signal (the maximum signal as determined by the assay design), 
“Min” signal (the background signal as determined by the assays 
design), and also “Mid” signal (this parameter estimates the signal 
variability at some point between the maximum and minimum 
signals).
Two different plate formats exist for the plate uniformity 
studies: interleaved-signal format – where all signals are on all 
plates but varied systematically, so that on all plates, on a given 
day, each signal is measured in each plate; and concentration–
response curve plate format – where a reference compound is 
tested at multiple concentrations with production control wells 
(Max and Min, Figure 2A). The last one also includes uniform 
signal plates for “Max” (Figure  2B) and “Min” (Figure  2C) 
where each signal is run uniformly instead of the concentra-
tion–response curve for the reference compound. In both 
cases, the recommended acceptance criterion is Z′ factor ≥0.4 
(which is comparable to a Signal Window ≥2), coefficient of 
variation <20%, absence of edge, drift or other spatial effects, 
and minimum significant ratio <3 or the normalized average 
Mid-signal should not translate into a twofold shift (within days 
or across any 2 days).
Replicate-Experiment Study
Replicate-experiment studies are used to formally evaluate the 
within-run assay variability and are a diagnostic and decision tool 
used to establish that the assay is ready to go into production by 
showing that the endpoints of the assay are reproducible over a 
range of potencies.
The analysis approach used in the replicate-experiment study 
is to estimate and factor out between-run variability, and then 
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FIGURe 3 | high-content imaging data for propidium iodide staining and ph3 detection. (A) Acumen screenshots of untreated (left) and nocodazole-treated 
HeLa cells (right). (B) Histograms showing cell cycle distribution generated after raw data processing from untreated (left) and nocodazole-treated cells (right).  
The G1 subpopulation is in cyan blue; S is represented in yellow, G2M phase in red, and cells with >4N DNA content are in pink. (C) Histogram showing pH3 signal 
after raw data processing from untreated (left) and nocodazole-treated cells (right).
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estimate the magnitude of within-run variability. The procedure 
has mainly three steps:
 1. Select 20–30 compounds that have potencies covering the 
concentration range being tested and, if applicable, efficacy 
measures that cover the range of interest. The compounds 
should be well spaced over these ranges.
 2. Run all compounds in each of two runs of the assay.
 3. Compare the two runs. A series of statistical parameters will 
be calculated (mean-ratio, ratio limits, minimum significant 
ratio, and limits of agreement). MSR should be <3 and both 
limits of agreement should be between 0.33 and 3.0.
After successfully passing both validation studies (plate 
uniformity and replicate experiment), the assay is ready and the 
different libraries of compounds can be tested.
For a more comprehensive explanation on HTS assay valida-
tion, please refer to Iversen et al. (14).
PRACtICAL eXAMPLes APPLIed to 
AURoRA INhIBItoRs
development of ph3s10 and PI 
Multiplexing Assay
To evaluate Aurora-A or -B phenotype for different libraries of 
compounds, a multiplexing assay monitoring pH3S10 and DNA 
content was developed.
Cell Model
HeLa cells (ATCC# CCL-2) are epithelial cells isolated from 
cervix adenocarcinoma. These cells were selected based on their 
MK5108 MLN8237 AZD1152
hAurora-A 
IC50 (nM) 1.1 1.9 97.9
hAurora-B
IC50 (nM) 8.6 6.3 2.3
A B C
D E F
FIGURe 4 | dose–response curves for Aurora kinases inhibitors in clinical trials [modified from Ref. (18)]. (A) Inhibition of recombinant human Aurora-A 
and -B in biochemical assays. (B) Inhibition profile for pH3S10 after 1h of exposure (NCI-H446 cells). (C) Inhibition profile for cell proliferation after 24 h of exposure 
(HeLa cells). (d,e) Accumulation profile for pH3S10 after 24 h of exposure (HeLa cells). (F) Accumulation profile for cells with 4N and >4N DNA content after 24 h of 
exposure (HeLa cells).
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morphology for the imaging assay and because of the selected 
target of interest.
The optimal cell seeding density was evaluated and 5000 
cells per well (96-well plates) was chosen as it produces a strong 
enough signal while cells remain well separated to allow single 
cell identification. To avoid loss of responsiveness, cells with as 
low passage number as possible were used and never exceeding 
a passage of 20. Cells were plated 18–24  h prior to compound 
dosing and were incubated at 37°C with 5% CO2.
Compound Treatment
DMSO tolerance experiments determined that 0.25% DMSO 
should not be exceeded. As the cell doubling time is around 20 h, 
24 h of incubation with compounds was chosen as an appropri-
ate dosing time that would allow monitoring changes in mitotic 
index.
To perform compounds dose–response titration, threefold 
serial dilutions (in complete growth media containing 0.75% 
DMSO) were carried out in 96-well plates. This created a 10-point 
curve starting from 20  μM (final concentration in the assay). 
Then, 50 μL of compound solution was transferred from a dilu-
tion plate onto a cell plate containing 100 μL of culture media.
Assay Performance
HeLa cells were incubated with compounds for 24 h at 37°C/5% CO2, 
fixed with Prefer (Anatech) for 30 min at room temperature, and 
permeated with 0.1% Triton X-100 in PBS for 15 min. After a couple 
of washing steps with PBS, cells were blocked with 1% BSA in PBS. 
Then, the blocking solution was removed and the primary antibody 
solution [rabbit anti-phospho-histone H3 (ser10), Millipore] was 
added to the cells (1:1000 in 1% BSA in PBS) and they were incubated 
overnight at 4°C with a gentle shake. Next day, the primary antibody 
was washed away with PBS and cells were treated with 1:1000 Alexa 
Fluor 488-conjugated secondary antibody for 1 h at room temperature 
in the dark. Finally, upon washing steps with PBS, cells were treated 
with 1.4 μg/mL PI solution containing 50 μg/mL ribonuclease for 2 h 
at room temperature (DNA staining). An Acumen Explorer (TTP 
Labtech) was used for reading and image analysis.
Nocodazole was used as a tool compound for assay validation. 
It is a molecule that affects microtubule dynamics by preventing 
polymerization. This will result in the activation of the spindle 
assembly checkpoint and, therefore, a cell cycle arrest at G2/M 
phase. As a negative control, untreated cells were used. This 
assay allows the measurement of several readouts with single cell 
resolution and we focused our interest mainly in the following: 
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cell number, 2N, 4N, >4N, and pH3S10. Aurora-B kinases are 
responsible for one of the classic modifications of chromatin 
in mitosis, phosphorylation of histone H3 on S10 (6), that is 
why pH3S10 was chosen as both mitotic marker and readout 
of Aurora-B inhibition. Data from treated and untreated cells 
are plotted to generate histograms that can be gated to separate 
diploid cells, tetraploid, and polyploid cells, and cells in S phase. 
As expected, nocodazole-treated cells show an accumulation in 
G2M as well as an accumulation of pH3 positive cells (Figure 3).
Results Interpretation and Phenotype 
deconvolution
To evaluate the phenotypic outcome of the assay and thus help 
with results’ interpretation, three molecules that are or have been 
in clinical trials showing different Aurora-A and -B selectivity pro-
files were selected: AZD1152, a selective Aurora-B inhibitor (15), 
and selective Aurora-A inhibitors, MLN8237 (16) and MK5108 
(17). These molecules were first tested in biochemical assays 
(Figure 4A) to confirm their potency against Aurora-A and -B.
By performing 10-point dose–response curves in the previ-
ously mentioned multiplexing assay, we evaluated the effect of 
the compounds in the different readouts. Those readouts allow 
distinguishing Aurora-A and -B phenotypes, whereas Aurora-A 
leads to mitotic arrest (increase of 4N subpopulation and pH3S10, 
and therefore cell proliferation inhibition), Aurora-B leads to 
endoreplication (increase of 4N but mainly >4N subpopulations, 
cell proliferation inhibition, and a decrease in pH3S10).
To confirm the Aurora-B phenotype of the compounds a sin-
gleplex assay was also developed, using NCI-H446 cells (human 
small cell lung carcinoma, ATCC# HTB-171) and evaluating 
inhibition of pH3S10 at a shorter time (1 h incubation, Figure 4B).
AZD1152 shows a clear Aurora-B phenotype with 
pH3S10 inhibition and accumulation of >4N subpopulation 
(Figures  4B,E,F), whereas MLN8237 and MK5108 show an 
Aurora-A phenotype with accumulation of pH3S10 positive 
cells and 4N subpopulation (Figures 4D,F). With regards to cell 
proliferation inhibition (Figure  4C), MK5108 seems to be less 
potent than the other two molecules.
In Figure 4D, we can see inside the red rectangle, a possible 
effect not related to Aurora-A inhibition (higher in MLN than 
in MK) when evaluating pH3S10. At high concentrations of 
these compounds, there is a decrease in this readout that might 
be a consequence of Aurora-B inhibition (as seen in Figure 4B). 
Although in Figure 4F, the % of 4N and >4N positive cells was 
represented as one readout, it could be separated into two to 
further differentiate Aurora-A and -B phenotype.
By looking at the cell cycle subpopulations, with this type of 
assay we can also identify effects caused by inhibition of other 
targets (e.g., G1S arrest for CDK4/6 inhibitors).
In vitro Pharmacological Characterization 
through Multiplexing Assays
To further extend the use of this technology, more in-depth assays 
can be designed for advanced molecules as a bridging step between 
A B
C D E
FIGURe 5 | Cell viability in vitro assays to determine the optimal pharmacological dose schedule for AZd1152, MLN8237, and MK5108 [modified 
from Ref. (18)]. (A,B) H446 cells. (C–e) MDA-MB-468 cells. NA*, not available.
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biochemical assays and in vivo assays. By using different exposure 
times to the compounds and performing washout experiments, 
we can try to investigate the in vitro pharmacology (required time 
on target and sustainability of the response). Adding different 
readouts as apoptosis or senescence will also help to identify the 
cause of cell proliferation inhibition.
The same molecules were used in an experiment to estimate 
the exposure time needed in two different cell lines, NCI-H446 
and MDA-MB-468 (human breast adenocarcinoma ATCC# 
HTB-132), to promote growth inhibition and achieve the desired 
phenotype (Figure 5). CellTiter-Glo® was used to evaluate cell 
viability inhibition as one of the cell lines (NCI-H446) is mixed, 
with both adherent and suspension cells. It seemed that at least 
24 h on target were required to promote cell growth inhibition.
High-content imaging follow-up experiments were performed 
in MDA-MB-468 to correlate cell proliferation inhibition with 
phenotypic readouts (% pH3S10 accumulation and % caspase 3 
induction) as well as to try to find the most appropriate dose of 
the compounds to promote these effects (Figure 6). As already 
shown in Figure 4C, MK5108 was found to be less potent than 
MLN8237 when used at the same dose. This observation cor-
relates with the two different readouts used in this experiment: 
caspase 3 (Figures  6A,B) and pH3S10 (Figures  6C,D), where 
MK5108 seems to require a higher dose (600  nM) and longer 
exposure time (72–144  h) to produce a considerable response, 
whereas MLN8237 seems to work at 200 nM and 48–72 h.
To summarize, we have reviewed a couple of multiplexing 
technologies focusing on HCI as a powerful technique for HTS. 
This technique can be used not only for screening purposes but 
also to go in-depth and try to characterize the in vitro pharmacol-
ogy of the molecules. This could build a bridge between in vitro 
and in vivo, saving resources and helping to design more appro-
priate in vivo experiments. All of this integrated in a flow scheme 
will generate key data to select the best candidate molecule (with 
desired properties such as oral administration, safety, and selec-
tivity) improving its possibilities to move into clinical trials.
A B
C D
FIGURe 6 | Phenotypic readouts, permanent exposure to MLN8237 and MK5108 (18). (A,B) Percentage of caspase 3 positive cells determination in a time 
course manner carried out in a range of compounds concentrations. n = 2 per conc. (C,d) Percentage of mitotic index determination in a time course manner 
carried out in a range of compounds concentrations. n = 2 per conc.
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